Vulvar and Vaginal Atrophy (VVA) Therapy Market Size & Share, by Symptoms (Vaginal Dryness, Burning Sensation in the Vagina, Dyspareunia, Urinary Tract Infection); Diagnosis (Pelvic Examination, Urine Test, Acid Balance Test); Treatment (Non-Hormonal Therapy, Hormonal Therapy, Laser Therapy); End-user (Hospitals, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4178
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Vulvar And Vaginal Atrophy (Vva) Therapy Landscape

top-features-companies
    • Daré Bioscience, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Almirall, S.A.
    • Viveve, Inc.
    • Lutronic Corporation
    • Venus Concept
    • ThermiGen, LLC
    • Alma Lasers LTD.
    • BTL
    • Fotona d.o.o.
    • TherapeuticsMD, Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Dare Bioscience, Inc. has announced the initiation of the DARE-VVA1’s Phase I/II trial to evaluate a proprietary investigational formulation for the non-hormonal treatment of moderate to severe vulvar and vaginal atrophy (VVA). DARE-VVA1 is a new intravaginal tamoxifen product developed to treat vulvar and vaginal atrophy.

  • TherapeuticsMD, Inc. announced the approval by the U.S. Food and Drug Administration for Imvexxy 4 mcg dose. Imvexxy 4 mcg is now a commercially available drug in the United States for the treatment of dyspareunia, which is a symptom of vulvar and vaginal atrophy.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4178
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of breast cancer and uterine cancer in women and the growing prevalence of UTI are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 11% over the forecast period, i.e., 2023-2035.

Concerns about vulvar and vaginal atrophy from cancer combination treatments are estimated to be the growth-hindering factors for market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Almirall, S.A., Viveve, Inc., Lutronic Corporation, Venus Concept, ThermiGen, LLC, Alma Lasers LTD., BTL, Fotona d.o.o., TherapeuticsMD, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by symptoms, diagnosis, treatment, end-user, and by region.

The hormonal therapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying